Developer docs
API playgroundTry for free, no card

Search company profiles

ExeVir Bio

Full company profile

uuid000289t

Namestring
ExeVir Bio
Legal namestring
ExeVir Bio BV
Websiteurl
exevir.com
Company typeenum
Private
Founded yearint
2020
Descriptiontext

ExeVir Bio is a Belgium-based, clinical-stage biopharmaceutical company founded in 2020 as a spin-out from VIB (Vlaams Instituut voor Biotechnologie), developing single-domain antibody (VHH/nanobody) therapeutics derived from camelid (llama) antibodies for infectious diseases. The company's core technology is a modular VHH platform that uses llama antibody fragments as building blocks to engineer multi-specific constructs capable of binding conserved and often hidden epitopes on viral proteins, providing broad cross-variant neutralization and reduced risk of immune escape; the constructs are stable, cost-effective, and produced using microbial systems such as Pichia pastoris. The pipeline includes XVR011 (completed Phase 1a/1b, targeting SARS-CoV-2), XVR012/XVR013/XVR014 (multi-epitope COVID-19 constructs targeting both S1 and S2 regions), and XVR021 (preclinical dengue program targeting all four serotypes), with primary focus on immunocompromised populations who do not benefit from vaccination.

The company targets two distinct end-patient populations: (1) immunocompromised individuals (~3% of Western populations) including cancer patients, transplant recipients, and those on immunosuppressive therapies who remain vulnerable to COVID-19 despite vaccines, and (2) populations in dengue-endemic regions (3.9 billion people across 125+ countries) where no specific antiviral therapeutics currently exist. ExeVir's business model is licensing- and partnership-driven: it is a clinical-stage biotech with no approved products, generating no commercial revenue today, and intends to monetize through out-licensing deals, co-development agreements, and royalty arrangements with pharmaceutical partners for later-stage development and commercialization. The company is funded by approximately EUR 42M in Series A equity (led by Fund+), EUR 25M in venture debt from the European Investment Bank, and EUR 18M+ in non-dilutive grants from VLAIO, SPW-Recherche, and EU sources, with manufacturing collaborations in place with UCB and Mithra Pharmaceuticals.

Short descriptiontext

ExeVir Bio is a Belgium-based clinical-stage biotech developing llama-derived single-domain antibody (VHH) therapeutics for infectious diseases, with a pipeline targeting COVID-19 (XVR011/012/013/014) and dengue (XVR021) for immunocompromised and at-risk populations, monetizing via future out-licensing and co-development partnerships.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersGhent, Belgium
HQ citystring
Ghent
HQ countrystring
Belgium
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
antibody therapeutics platform, nanobody drug development, infectious disease treatments, VHH antibody technology, biopharmaceutical pipeline development
Industry2 codes
PRIMARYHLAAAIAB
Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAAAF
Bispecific & Multispecific Antibodies
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Biopharmaceutical Therapeutics
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Therapeutic Development and Commercialization
TypeLicensing Royalties
Description

ExeVir is a clinical-stage company developing antibody therapeutics. Revenue will be generated through out-licensing/partnership deals with pharmaceutical companies for co-development and commercialization, as well as potential direct product sales upon regulatory approval. The company is seeking strategic partnerships for co-development of novel antibody therapies.

exevir.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

ExeVir Bio develops single-domain antibody therapeutics (VHH nanobodies) derived from camelid (llama) antibodies for the prevention and treatment of infectious diseases. The company's pipeline focuses on multi-specific antibody constructs targeting COVID-19 (lead asset XVR011) and dengue (XVR021), with manufacturing enabled by the Pichia pastoris expression system. Target populations include immunocompromised patients for whom conventional vaccines and monoclonal antibodies show reduced efficacy.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • XVR011 demonstrated neutralization of all SARS-CoV-2 variants of concern including Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), Delta (B.1.617.2), and Omicron BA.5, with no impact on potency observed.
+3 more records
Product overview1 text field

ExeVir Bio is a clinical-stage biotech company developing novel antibody therapies using its proprietary VHH (Variable Domain of Heavy-chain) technology platform derived from llama antibodies. The company is building a pipeline of antibody therapies for infectious diseases with an initial focus on COVID-19 and dengue. The COVID-19 portfolio includes XVR011 (lead candidate that completed Phase 1 studies), XVR012 (cocktail of XVR013 and XVR014 targeting multiple epitopes), and other constructs targeting conserved regions of the SARS-CoV-2 spike protein. The dengue program includes XVR021 targeting all four dengue serotypes. The modular VHH platform enables multi-specific constructs that are stable, cost-effective, and robust against viral mutations.

Product and service1 record
1XVR011
Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership6 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-07-15
Description

Mithra Pharmaceuticals (Euronext Brussels: MITRA) entered a manufacturing collaboration with ExeVir for innovative COVID-19 treatments. Mithra provides GMP manufacturing capabilities for ExeVir's clinical trial materials.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

VIB is ExeVir's founding research partner and spin-out origin. VIB scientists (Professors Xavier Saelens and Nico Callewaert from VIB-UGent) developed the VHH technology platform. VIB provides ongoing research collaboration and drug discovery capabilities through VIB Discovery Sciences. VIB is also an investor. Jérôme Van Biervliet, Managing Director of VIB, serves on ExeVir's Board of Directors.

3UCB / UCB Ventures
Strategic tierCoreTypeStrategic or Co-development Partner
Description

UCB Ventures is an investor in ExeVir and a strategic partner providing manufacturing and formulation support. UCB assisted in generating the lead candidate and is producing GMP batches for clinical trials. UCB is listed on Euronext Brussels with €5.3 billion revenue in 2020. Erica Whittaker, VP & Head of UCB Ventures, serves on ExeVir's Board of Directors.

exevir.com
Strategic tierSupportingTypeStrategic or Co-development Partner
Description

Professor Johan Neyts and team at KU Leuven's Rega Institute collaborated on preclinical neutralization studies for ExeVir's antibody candidates, including demonstrating in vitro neutralization activity against SARS-CoV-2 variants of concern.

5National Institute of Allergy and Infectious Diseases (NIAID)
Strategic tierSupportingTypeStrategic or Co-development Partner
Description

Laboratory of Barney Graham at NIAID (Vaccine Research Center) collaborated with VIB scientists on the development of the VHH technology platform for coronavirus neutralization, contributing to foundational research published in Cell.

exevir.com
Strategic tierSupportingTypeStrategic or Co-development Partner
Description

Laboratory of Jason McLellan at the University of Texas at Austin collaborated with VIB scientists on structural characterization of VHH antibodies binding to coronavirus spike proteins, contributing to the foundational Cell publication.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

AstraZeneca developed Evusheld (tixagevimab/cilgavimab) for COVID-19 prophylaxis in immunocompromised patients — the same target population as ExeVir's lead programs. Comparable as a large incumbent directly addressing ExeVir's intended market.

TypeBroad incumbent
Description

Lilly developed bebtelovimab for COVID-19 in partnership with AbCellera and has a deep antibody therapeutics pipeline. Comparable as a large-pharma incumbent in the COVID-19 antibody space where ExeVir is also competing for attention.

TypeBroad incumbent
Description

Regeneron developed the REGEN-COV COVID-19 antibody cocktail and is the gold-standard large-cap antibody platform. Comparable as an incumbent antibody developer in infectious disease, though vastly larger and more diversified.

TypeDirect peer
Description

Vir Biotechnology develops antibody-based therapeutics for infectious diseases, including sotrovimab for COVID-19 and influenza programs. Directly comparable as a clinical-to-commercial infectious-disease antibody developer with similar scientific ambitions.

TypeDirect peer
Description

Argenx is the leading commercial-stage VHH/nanobody platform company, with efgartigimod approved for myasthenia gravis and a broad autoimmune pipeline. It is the closest direct comparable to ExeVir's VHH-based approach, though focused on autoimmune rather than infectious disease.

6Harbour BioMed
TypeDirect peer
Description

Harbour BioMed operates a nanobody platform (Harbour Antibodies) for therapeutic development across oncology and immunology. It is a directly comparable single-domain antibody platform peer, with smaller scale than Argenx but similar technology underpinnings.

TypeOthers
Description

ImmunoPrecise is a contract research organization specializing in antibody discovery and development, including custom VHH/nanobody generation services. Comparable as an adjacent ecosystem participant providing capabilities similar to those underpinning ExeVir's platform.

TypeDirect peer
Description

AbCellera operates an antibody discovery platform that powered multiple COVID-19 antibody programs (including bamlanivimab with Eli Lilly). Comparable as an antibody discovery engine and as an infectious-disease antibody developer with similar partnership-driven business model.

TypeEmerging player
Description

Adagene is a clinical-stage antibody platform company using computational and engineering approaches to develop precision antibodies, primarily in oncology. Comparable as an emerging platform-based antibody developer, though with a different therapeutic focus.

TypeEmerging player
Description

Inhibrx develops single-domain antibody-based therapeutics (e.g., INBRX-101 in oncology). Comparable as a clinical-stage nanobody/single-domain antibody developer, though focused on oncology rather than infectious disease.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature11 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors11 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

ExeVir Bio

Biopharmaceutical Therapeuticsexevir.com

ExeVir Bio is a Belgium-based clinical-stage biotech developing llama-derived single-domain antibody (VHH) therapeutics for infectious diseases, with a pipeline targeting COVID-19 (XVR011/012/013/014) and dengue (XVR021) for immunocompromised and at-risk populations, monetizing via future out-licensing and co-development partnerships.

What ExeVir Bio does

ExeVir Bio is a Belgium-based, clinical-stage biopharmaceutical company founded in 2020 as a spin-out from VIB (Vlaams Instituut voor Biotechnologie), developing single-domain antibody (VHH/nanobody) therapeutics derived from camelid (llama) antibodies for infectious diseases. The company's core technology is a modular VHH platform that uses llama antibody fragments as building blocks to engineer multi-specific constructs capable of binding conserved and often hidden epitopes on viral proteins, providing broad cross-variant neutralization and reduced risk of immune escape; the constructs are stable, cost-effective, and produced using microbial systems such as Pichia pastoris. The pipeline includes XVR011 (completed Phase 1a/1b, targeting SARS-CoV-2), XVR012/XVR013/XVR014 (multi-epitope COVID-19 constructs targeting both S1 and S2 regions), and XVR021 (preclinical dengue program targeting all four serotypes), with primary focus on immunocompromised populations who do not benefit from vaccination.

The company targets two distinct end-patient populations: (1) immunocompromised individuals (~3% of Western populations) including cancer patients, transplant recipients, and those on immunosuppressive therapies who remain vulnerable to COVID-19 despite vaccines, and (2) populations in dengue-endemic regions (3.9 billion people across 125+ countries) where no specific antiviral therapeutics currently exist. ExeVir's business model is licensing- and partnership-driven: it is a clinical-stage biotech with no approved products, generating no commercial revenue today, and intends to monetize through out-licensing deals, co-development agreements, and royalty arrangements with pharmaceutical partners for later-stage development and commercialization. The company is funded by approximately EUR 42M in Series A equity (led by Fund+), EUR 25M in venture debt from the European Investment Bank, and EUR 18M+ in non-dilutive grants from VLAIO, SPW-Recherche, and EU sources, with manufacturing collaborations in place with UCB and Mithra Pharmaceuticals.

ExeVir Bio firmographics

Firmographics
Name
ExeVir Bio
Legal name
ExeVir Bio BV
Website
https://exevir.com
Company type
Private
Founded year
2020
Operating status
Operating
Headcount range
1–10 employees
Short description
ExeVir Bio is a Belgium-based clinical-stage biotech developing llama-derived single-domain antibody (VHH) therapeutics for infectious diseases, with a pipeline targeting COVID-19 (XVR011/012/013/014) and dengue (XVR021) for immunocompromised and at-risk populations, monetizing via future out-licensing and co-development partnerships.
Ownership category
akta.pro rank

ExeVir Bio industry classification

Industry
Product category
Biopharmaceutical Therapeutics
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAAIAB
Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAAAF
Bispecific & Multispecific Antibodies
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)

Keywords

  • Antibody therapeutics platform
  • Nanobody drug development
  • Infectious disease treatments
  • VHH antibody technology
  • Biopharmaceutical pipeline development

Where ExeVir Bio is headquartered

Location

Headquarters

HQ city
Ghent
HQ country
Belgium
HQ region
Europe

Offices2 records

Markets served

ExeVir Bio business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

  1. Therapeutic Development and Commercialization: ExeVir is a clinical-stage company developing antibody therapeutics. Revenue will be generated through out-licensing/partnership deals with pharmaceutical companies for co-development and commercialization, as well as potential direct product sales upon regulatory approval. The company is seeking strategic partnerships for co-development of novel antibody therapies.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels5 records

ExeVir Bio product offering

Product offering

Core offering

ExeVir Bio develops single-domain antibody therapeutics (VHH nanobodies) derived from camelid (llama) antibodies for the prevention and treatment of infectious diseases. The company's pipeline focuses on multi-specific antibody constructs targeting COVID-19 (lead asset XVR011) and dengue (XVR021), with manufacturing enabled by the Pichia pastoris expression system. Target populations include immunocompromised patients for whom conventional vaccines and monoclonal antibodies show reduced efficacy.

Product overview

ExeVir Bio is a clinical-stage biotech company developing novel antibody therapies using its proprietary VHH (Variable Domain of Heavy-chain) technology platform derived from llama antibodies. The company is building a pipeline of antibody therapies for infectious diseases with an initial focus on COVID-19 and dengue. The COVID-19 portfolio includes XVR011 (lead candidate that completed Phase 1 studies), XVR012 (cocktail of XVR013 and XVR014 targeting multiple epitopes), and other constructs targeting conserved regions of the SARS-CoV-2 spike protein. The dengue program includes XVR021 targeting all four dengue serotypes. The modular VHH platform enables multi-specific constructs that are stable, cost-effective, and robust against viral mutations.

Differentiator

Problem solved

Functional benefit

Products and services

  • XVR011

Quantifiable outcome

  • XVR011 demonstrated neutralization of all SARS-CoV-2 variants of concern including Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), Delta (B.1.617.2), and Omicron BA.5, with no impact on potency observed.
  • +3 more outcomes

Companies that use ExeVir Bio

Customer profile

Segments2 records

Ideal customer profiles1 record

ExeVir Bio technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature11 records

ExeVir Bio partnerships and signals

Strategic signal

Partnerships

Six partnerships are on record, tiered core and supporting.

  • Mithra PharmaceuticalscoreStrategic or Co-development Partner · 15 July 2021Mithra Pharmaceuticals (Euronext Brussels: MITRA) entered a manufacturing collaboration with ExeVir for innovative COVID-19 treatments. Mithra provides GMP manufacturing capabilities for ExeVir's clinical trial materials.
  • VIB (Vlaams Instituut voor Biotechnologie)coreStrategic or Co-development PartnerVIB is ExeVir's founding research partner and spin-out origin. VIB scientists (Professors Xavier Saelens and Nico Callewaert from VIB-UGent) developed the VHH technology platform. VIB provides ongoing research collaboration and drug discovery capabilities through VIB Discovery Sciences. VIB is also an investor. Jérôme Van Biervliet, Managing Director of VIB, serves on ExeVir's Board of Directors.
  • UCB / UCB VenturescoreStrategic or Co-development PartnerUCB Ventures is an investor in ExeVir and a strategic partner providing manufacturing and formulation support. UCB assisted in generating the lead candidate and is producing GMP batches for clinical trials. UCB is listed on Euronext Brussels with €5.3 billion revenue in 2020. Erica Whittaker, VP & Head of UCB Ventures, serves on ExeVir's Board of Directors.
  • Rega Institute (KU Leuven)supportingStrategic or Co-development PartnerProfessor Johan Neyts and team at KU Leuven's Rega Institute collaborated on preclinical neutralization studies for ExeVir's antibody candidates, including demonstrating in vitro neutralization activity against SARS-CoV-2 variants of concern.
  • National Institute of Allergy and Infectious Diseases (NIAID)supportingStrategic or Co-development PartnerLaboratory of Barney Graham at NIAID (Vaccine Research Center) collaborated with VIB scientists on the development of the VHH technology platform for coronavirus neutralization, contributing to foundational research published in Cell.
  • University of Texas at AustinsupportingStrategic or Co-development PartnerLaboratory of Jason McLellan at the University of Texas at Austin collaborated with VIB scientists on structural characterization of VHH antibodies binding to coronavirus spike proteins, contributing to the foundational Cell publication.

Scale indicators5 records

Recent moves7 records

Expansion highlights6 records

ExeVir Bio competitors and assessment

Company assessment

Broad incumbents

  • AstraZeneca: AstraZeneca developed Evusheld (tixagevimab/cilgavimab) for COVID-19 prophylaxis in immunocompromised patients — the same target population as ExeVir's lead programs. Comparable as a large incumbent directly addressing ExeVir's intended market.
  • Eli Lilly: Lilly developed bebtelovimab for COVID-19 in partnership with AbCellera and has a deep antibody therapeutics pipeline. Comparable as a large-pharma incumbent in the COVID-19 antibody space where ExeVir is also competing for attention.
  • Regeneron Pharmaceuticals: Regeneron developed the REGEN-COV COVID-19 antibody cocktail and is the gold-standard large-cap antibody platform. Comparable as an incumbent antibody developer in infectious disease, though vastly larger and more diversified.

Direct peers

  • Vir Biotechnology: Vir Biotechnology develops antibody-based therapeutics for infectious diseases, including sotrovimab for COVID-19 and influenza programs. Directly comparable as a clinical-to-commercial infectious-disease antibody developer with similar scientific ambitions.
  • Argenx: Argenx is the leading commercial-stage VHH/nanobody platform company, with efgartigimod approved for myasthenia gravis and a broad autoimmune pipeline. It is the closest direct comparable to ExeVir's VHH-based approach, though focused on autoimmune rather than infectious disease.
  • Harbour BioMed: Harbour BioMed operates a nanobody platform (Harbour Antibodies) for therapeutic development across oncology and immunology. It is a directly comparable single-domain antibody platform peer, with smaller scale than Argenx but similar technology underpinnings.
  • AbCellera Biologics: AbCellera operates an antibody discovery platform that powered multiple COVID-19 antibody programs (including bamlanivimab with Eli Lilly). Comparable as an antibody discovery engine and as an infectious-disease antibody developer with similar partnership-driven business model.

Others

  • ImmunoPrecise Antibodies: ImmunoPrecise is a contract research organization specializing in antibody discovery and development, including custom VHH/nanobody generation services. Comparable as an adjacent ecosystem participant providing capabilities similar to those underpinning ExeVir's platform.

Emerging players

  • Adagene: Adagene is a clinical-stage antibody platform company using computational and engineering approaches to develop precision antibodies, primarily in oncology. Comparable as an emerging platform-based antibody developer, though with a different therapeutic focus.
  • Inhibrx Biosciences: Inhibrx develops single-domain antibody-based therapeutics (e.g., INBRX-101 in oncology). Comparable as a clinical-stage nanobody/single-domain antibody developer, though focused on oncology rather than infectious disease.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

ExeVir Bio social profiles

Digital presence

ExeVir Bio financial estimates

Financial estimate

Revenue estimate

Valuation estimate

ExeVir Bio leadership team

Management profile

Number of profiles

Profiles8 records

ExeVir Bio funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors11 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

ExeVir Bio M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ExeVir Bio

What does ExeVir Bio do?

ExeVir Bio develops single-domain antibody therapeutics (VHH nanobodies) derived from camelid (llama) antibodies for the prevention and treatment of infectious diseases. The company's pipeline focuses on multi-specific antibody constructs targeting COVID-19 (lead asset XVR011) and dengue (XVR021), with manufacturing enabled by the Pichia pastoris expression system. Target populations include immunocompromised patients for whom conventional vaccines and monoclonal antibodies show reduced efficacy.

Is ExeVir Bio a public or private company?

ExeVir Bio is a private company. It is classified as venture growth investor backed and is currently operating.

When was ExeVir Bio founded?

ExeVir Bio was founded in 2020. It employs 1 to 10 people.

Where is ExeVir Bio based?

ExeVir Bio is headquartered in Ghent, Belgium, in the Europe region.

How does ExeVir Bio make money?

One revenue line is on record: therapeutic Development and Commercialization.

Who are ExeVir Bio's main competitors?

Broad incumbents on record are AstraZeneca, Eli Lilly and Regeneron Pharmaceuticals. Direct peers are Vir Biotechnology, Argenx, Harbour BioMed and AbCellera Biologics. ImmunoPrecise Antibodies is listed as an others. Emerging players are Adagene and Inhibrx Biosciences.

Does ExeVir Bio have an API?

No public API is recorded for ExeVir Bio.

What industry is ExeVir Bio in?

ExeVir Bio's product category is Biopharmaceutical Therapeutics. Its primary akta.pro industry code is HLAAAIAB, Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering), with a secondary code of HLAAAAAF, Bispecific & Multispecific Antibodies. Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
FinSMEsExeVir Announces Michael Garrett as New CEOExeVir Bio appointed Michael Garrett as CEO, effective 1 December 2024, and he will join its Board of Directors. Garrett, a patent attorney and former executive at Flamingo Therapeutics, brings experience in business development and IP from roles at Scynexis and BTG plc.GlobeNewswireExeVir Announces Michael Garrett as New Chief Executive OfficerExeVir Bio appointed Michael Garrett as CEO, effective 1 December 2024, and he will join the Board. The company plans its First in Human clinical trial for XVR013m in 2025. The VHH platform is also being leveraged for dengue and pandemic preparedness.GlobeNewswireEmpowering the Immunocompromised and Elderly: ExeVir Bio presents promising XVR013m data at ID Week 2024ExeVir Bio will present XVR013m, a VHH-FC antibody targeting SARS-CoV-2's S2 subunit, at ID Week 2024 in Los Angeles. The company aims to protect immunocompromised and elderly populations, with clinical development planned to start in 2025.GlobeNewswireExeVir Bio Announces Exceptional Virus Neutralization Potency of its Variant-proof XVR013m Antibody Against the SARS-CoV-2 Variant JN.1ExeVir Bio announced new data showing its antibody XVR013m neutralizes SARS-CoV-2 variant JN.1 with an IC50 of 2.8 ng/mL, unchanged from prior variants. The company plans to start clinical development of XVR013m in 2025 for immunocompromised and elderly populations.TmcnetExeVir Bio Announces Exceptional Virus Neutralization Potency of its Variant-proof XVR013m Antibody Against the SARS-CoV-2 Variant JN.1ExeVir Bio announced new data showing its antibody XVR013m neutralizes SARS-CoV-2 variant JN.1 with an IC50 of 2.8 ng/mL, unchanged from prior variants. The company plans to start clinical development of XVR013m in 2025 for immunocompromised and elderly populations.YahooExeVir Bio Announces Exceptional Virus Neutralization Potency of its Variant-proof XVR013m Antibody Against the SARS-CoV-2 Variant JN.1ExeVir Bio announced new data showing its antibody XVR013m neutralizes SARS-CoV-2 variant JN.1 with an IC50 of 2.8 ng/mL, unchanged from prior variants. The company plans to start clinical development of XVR013m in 2025 for immunocompromised and elderly populations.GlobeNewswireExeVir Bio Announces Positive Virus Neutralization Data for XVR012 Against Emerging COVID-19 Omicron VariantsExeVir Bio announced new data showing its XVR012 cocktail neutralizes circulating Omicron variants, including E.G.5.1, HV.1, and BA.2.86.1, with an IC50 range of 0.8 to 1.8 ng/mL. The company plans to start clinical development of XVR012 and its components in 2024.GlobeNewswireExeVir Bio Awarded EUR 1.6m Grant for Dengue ResearchExeVir Bio received a two-year EUR 1.6 million R&D grant from Flanders Innovation & Entrepreneurship for pre-clinical dengue research. The company will use its VHH antibody platform to develop multi-specific antibodies against all four dengue serotypes. The grant supports work beyond COVID-19, with XVR012 targeting dengue and XVR031 for pandemic preparedness.GlobeNewswireExeVir Bio Awarded EUR 1.6m Grant for Dengue ResearchExeVir Bio has been awarded a two-year, EUR 1.6 million research and development grant by the Flemish government agency VLAIO to support pre-clinical studies for dengue therapeutics. The funding aims to leverage ExeVir's llama-derived antibody technology to develop multi-specific antibodies capable of providing prophylactic and therapeutic protection against all four dengue virus serotypes.BioSpaceExeVir Bio Awarded EUR 1.6m Grant for Dengue ResearchExeVir Bio has been awarded a two-year, EUR 1.6 million research and development grant by Flanders Innovation & Entrepreneurship (VLAIO) to fund pre-clinical studies for dengue therapeutics. The funding supports the application of ExeVir's llama-derived antibody technology to address the global health threat posed by dengue, for which no specific antiviral treatments currently exist.